Cytochrome P450 1B1 (CYP1B1) has emerged as a critical enzyme in cancer pathophysiology due to its dual role in both xenobiotic metabolism and endogenous hormone regulation. Over-expression of CYP1B1 ...
Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from the 2011 ASCO ...
Diseases Like CKD, Cancers, and Psoriasis Can Benefit from the Blocking of CYP24 Activity Emerging data from new research suggests that abnormally elevated CYP24 expression contributes to the ...
The introduction of COVID-19 therapies containing ritonavir has markedly expanded the scope of use for this medicine. As a strong cytochrome P450 3A4 inhibitor, the use of ritonavir is associated with ...
An interdisciplinary research team at The University of Texas at San Antonio has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart ...
An interdisciplinary research team has successfully developed an innovative inhibitor that shows promise in fighting obesity and potentially preventing heart disease. The team developed an ...
Cytokinetics received U.S. FDA approval for MYQORZO on December 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results